Skip to main content

Lyme Borreliosis, Nervous System

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
VLA15 with AlumPhase 11 trial
Active Trials
NCT03010228Completed179Est. Jan 2019
Valneva
ValnevaAustria - Vienna
1 program
1
VLA15 with AlumPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerVLA15 with Alum

Clinical Trials (1)

Total enrollment: 179 patients across 1 trials

NCT03010228PfizerVLA15 with Alum

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Start: Jan 2017Est. completion: Jan 2019179 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lyme Borreliosis, Nervous System | Pipeline & Competitive Landscape | Formulate